Comprehensive Stock Comparison
Compare Mineralys Therapeutics, Inc. (MLYS) vs United Therapeutics Corporation (UTHR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | MLYS | Beta 0.40 vs UTHR's 0.43 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MLYS | +220.1% vs UTHR's +57.4% |
| Efficiency (ROA) | UTHR | 16.9% ROA vs MLYS's -28.6%, ROIC 21.1% vs -107.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hypertension and cardiovascular diseases. It generates no revenue currently but aims to monetize its lead candidate lorundrostat — a selective aldosterone synthase inhibitor — through future drug approvals and commercialization. The company's competitive advantage lies in its targeted approach to aldosterone inhibition, which addresses a specific biological pathway in treatment-resistant hypertension.
United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other rare diseases. It generates revenue primarily from its portfolio of PAH treatments — including Remodulin, Tyvaso, and Orenitram — which account for the vast majority of its sales. The company's competitive advantage lies in its deep expertise in prostacyclin therapies and its vertically integrated manufacturing capabilities for complex drug delivery systems.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
UTHR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). MLYS leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
UTHR and MLYS operate at a comparable scale, with $3.2B and $0 in trailing revenue.
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $3.2B |
| EBITDAEarnings before interest/tax | -$184M | $1.6B |
| Net IncomeAfter-tax profit | -$171M | $1.3B |
| Free Cash FlowCash after capex | -$171M | $1.0B |
| Gross MarginGross profit ÷ Revenue | — | +87.9% |
| Operating MarginEBIT ÷ Revenue | — | +46.9% |
| Net MarginNet income ÷ Revenue | — | +41.9% |
| FCF MarginFCF ÷ Revenue | — | +32.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +7.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +54.0% | +23.7% |
Valuation Metrics
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| Market CapShares × price | $2.3B | $22.0B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $20.4B |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | 18.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.90x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.94x |
| EV / EBITDAEnterprise value multiple | — | 12.95x |
| Price / SalesMarket cap ÷ Revenue | — | 6.91x |
| Price / BookPrice ÷ Book value/share | 7.43x | 3.40x |
| Price / FCFMarket cap ÷ FCF | — | 21.13x |
Profitability & Efficiency
UTHR delivers a 18.8% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-30 for MLYS. On the Piotroski fundamental quality scale (0–9), UTHR scores 7/9 vs MLYS's 1/9, reflecting strong financial health.
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -29.7% | +18.8% |
| ROA (TTM)Return on assets | -28.6% | +16.9% |
| ROICReturn on invested capital | -107.3% | +21.1% |
| ROCEReturn on capital employed | -89.0% | +21.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 7 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$114M | -$1.6B |
| Cash & Equiv.Liquid assets | $114M | $1.6B |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | 88.89x |
Total Returns (with DRIP)
A $10,000 investment in UTHR five years ago would be worth $29,421 today (with dividends reinvested), compared to $15,868 for MLYS. Over the past 12 months, MLYS leads with a +220.1% total return vs UTHR's +57.4%. The 3-year compound annual growth rate (CAGR) favors UTHR at 27.0% vs MLYS's 18.1% — a key indicator of consistent wealth creation.
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | +1.4% |
| 1-Year ReturnPast 12 months | +220.1% | +57.4% |
| 3-Year ReturnCumulative with dividends | +64.6% | +104.8% |
| 5-Year ReturnCumulative with dividends | +58.7% | +194.2% |
| 10-Year ReturnCumulative with dividends | +58.7% | +313.2% |
| CAGR (3Y)Annualised 3-year return | +18.1% | +27.0% |
Risk & Volatility
MLYS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than UTHR's 0.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UTHR currently trades 93.8% from its 52-week high vs MLYS's 61.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.40x | 0.43x |
| 52-Week HighHighest price in past year | $47.65 | $537.00 |
| 52-Week LowLowest price in past year | $8.69 | $266.98 |
| % of 52W HighCurrent price vs 52-week peak | +61.4% | +93.8% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 58.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 274K |
Analyst Outlook
Wall Street rates MLYS as "Buy" and UTHR as "Buy". Consensus price targets imply 77.7% upside for MLYS (target: $52) vs 11.8% for UTHR (target: $563).
| Metric | MLYSMineralys Therape… | UTHRUnited Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $52.00 | $563.17 |
| # AnalystsCovering analysts | 8 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 23 | Feb 26 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | 100 | 167.41 | +67.4% |
| United Therapeutics… (UTHR) | 100 | 193.96 | +94.0% |
United Therapeutics… (UTHR) returned +194% over 5 years vs Mineralys Therapeut… (MLYS)'s +59%. A $10,000 investment in UTHR 5 years ago would be worth $29,421 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | $0.00 | $0.00 | — |
| United Therapeutics… (UTHR) | $1.6B | $3.2B | +99.1% |
United Therapeutics Corporation's revenue grew from $1.6B (2016) to $3.2B (2025) — a 7.9% CAGR.
Chart 3P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | 15.9 | 17.5 | +10.1% |
United Therapeutics Corporation has traded in a 8x–22x P/E range over 8 years; current trailing P/E is ~18x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | -0.74 | -3.66 | -394.6% |
| United Therapeutics… (UTHR) | 15.25 | 27.86 | +82.7% |
United Therapeutics Corporation's EPS grew from $15.25 (2016) to $27.86 (2025) — a 7% CAGR.
Chart 5Free Cash Flow — 5 Years
Mineralys Therapeutics, Inc. generated $-166M FCF in 2024 (-1043% vs 2021). United Therapeutics Corporation generated $1B FCF in 2025 (+118% vs 2021).
MLYS vs UTHR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MLYS or UTHR a better buy right now?
United Therapeutics Corporation (UTHR) offers the better valuation at 18.1x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate Mineralys Therapeutics, Inc. (MLYS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLYS or UTHR?
Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +194.2%, compared to +58.7% for Mineralys Therapeutics, Inc. (MLYS). A $10,000 investment in UTHR five years ago would be worth approximately $29K today (assuming dividends reinvested). Over 10 years, the gap is even starker: UTHR returned +313.2% versus MLYS's +58.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLYS or UTHR?
By beta (market sensitivity over 5 years), Mineralys Therapeutics, Inc. (MLYS) is the lower-risk stock at 0.40β versus United Therapeutics Corporation's 0.43β — meaning UTHR is approximately 9% more volatile than MLYS relative to the S&P 500.
04Which has better profit margins — MLYS or UTHR?
United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.9% net margin versus 0.0% for Mineralys Therapeutics, Inc. — meaning it keeps 41.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 46.9% versus 0.0% for MLYS. At the gross margin level — before operating expenses — UTHR leads at 87.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is MLYS or UTHR more undervalued right now?
Analyst consensus price targets imply the most upside for MLYS: 77.7% to $52.00.
06Which pays a better dividend — MLYS or UTHR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MLYS or UTHR better for a retirement portfolio?
For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43), +313.2% 10Y return). Both have compounded well over 10 years (UTHR: +313.2%, MLYS: +58.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MLYS and UTHR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.